Domagrozumab is an anti-myostatin humanized monoclonal antibody with a KD value of 2.6 pM for human myostatin. Domagrozumab induces muscle anabolic activity. Domagrozumab can be used in research of duchenne muscular dystrophy (DMD).
Domagrozumab (PF-06252616) inhibits human myostatin signaling activity with an IC50 value of < 1 nM[1].
Domagrozumab (PF-06252616; 10 and 30 mg/kg; i.v.) increases myostatin levels in a dose-dependent manner and induces skeletal muscle hypertrophy in cynomolgus monkeys[1].
References:
[1]. St Andre M, et, al. A mouse anti-myostatin antibody increases muscle mass and improves muscle strength and contractility in the mdx mouse model of Duchenne muscular dystrophy and its humanized equivalent, domagrozumab (PF-06252616), increases muscle volume in cynomolgus monkeys. Skelet Muscle. 2017 Nov 9;7(1):25.